BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/16/2021 7:46:10 AM | Browse: 630 | Download: 1856
 |
Received |
|
2021-02-03 06:27 |
|
Peer-Review Started |
|
2021-02-03 06:32 |
|
First Decision by Editorial Office Director |
|
2021-08-19 19:20 |
|
Return for Revision |
|
2021-08-19 19:20 |
|
Revised |
|
2021-09-01 04:04 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-12-07 03:16 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-12-08 06:08 |
|
Articles in Press |
|
2021-12-08 06:08 |
|
Edit the Manuscript by Language Editor |
|
2021-11-23 07:49 |
|
Typeset the Manuscript |
|
2021-12-13 06:43 |
|
Publish the Manuscript Online |
|
2021-12-16 07:46 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Eiji Kawasaki, Yuko Nakano, Takahiro Fukuyama, Aira Uchida, Yoko Sagara, Hidekazu Tamai, Masayuki Tojikubo, Yuji Hiromatsu and Nobuhiko Koga |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eiji Kawasaki, MD, PhD, Director, Director, Department of Diabetes and Endocrinology, Shin-Koga Hospital, 120 Tenjin-cho, Kurume 830-8577, Japan. e-kawasaki@tenjinkai.or.jp |
| Key Words |
Omarigliptin; Once-weekly dipeptidyl peptidase-4 inhibitor; Real-world practice; Retrospective study; Type 2 diabetes |
| Core Tip |
This paper reported on the efficacy of omarigliptin in Japanese patients with type 2 diabetes who had previously received treatment with other glucose-lowering agents. The present study demonstrated that administering omarigliptin as add-on therapy or switching to it from sitagliptin and linagliptin, but not vildagliptin, provides more effective glycemic control. Ultimately, these findings should help decision-making in the actual clinical setting when selecting and using dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. |
| Publish Date |
2021-12-16 07:46 |
| Citation |
Kawasaki E, Nakano Y, Fukuyama T, Uchida A, Sagara Y, Tamai H, Tojikubo M, Hiromatsu Y, Koga N. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes. World J Diabetes 2021; 12(12): 2087-2095 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i12/2087.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i12.2087 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
